PCSA vs. RDHL, OBSV, CYCN, ORGS, AWH, EVAX, ABVC, GLTO, EDSA, and NLSP
Should you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include RedHill Biopharma (RDHL), ObsEva (OBSV), Cyclerion Therapeutics (CYCN), Orgenesis (ORGS), Aspira Women's Health (AWH), Evaxion Biotech A/S (EVAX), ABVC BioPharma (ABVC), Galecto (GLTO), Edesa Biotech (EDSA), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry.
Processa Pharmaceuticals vs.
Processa Pharmaceuticals (NASDAQ:PCSA) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
RedHill Biopharma received 412 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. Likewise, 67.03% of users gave RedHill Biopharma an outperform vote while only 60.00% of users gave Processa Pharmaceuticals an outperform vote.
Processa Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.68, indicating that its share price is 268% more volatile than the S&P 500.
91.9% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are held by institutional investors. 13.0% of Processa Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of RedHill Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
RedHill Biopharma's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.
RedHill Biopharma has higher revenue and earnings than Processa Pharmaceuticals.
Processa Pharmaceuticals currently has a consensus price target of $6.00, indicating a potential upside of 833.13%. Given Processa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Processa Pharmaceuticals is more favorable than RedHill Biopharma.
In the previous week, Processa Pharmaceuticals had 2 more articles in the media than RedHill Biopharma. MarketBeat recorded 8 mentions for Processa Pharmaceuticals and 6 mentions for RedHill Biopharma. Processa Pharmaceuticals' average media sentiment score of 0.99 beat RedHill Biopharma's score of -0.33 indicating that Processa Pharmaceuticals is being referred to more favorably in the media.
Summary
Processa Pharmaceuticals and RedHill Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Processa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Processa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PCSA) was last updated on 2/4/2025 by MarketBeat.com Staff
